News

Our President and COO Kathryn Corzo talks with editor Brian Buntz from Drug Discovery & Development.

Partnership to build a platform for the development of safer and more efficient genetic engineering of human cells for cell therap...

bit.bio received a gold award for its participation in the Green Impact awards for sustainability.

BlueRock Therapeutics and bit.bio announce collaboration and option agreement for the discovery & manufacture of regulatory T cell...

In this episode of the SynBioBeta podcast, bit.bio CEO Mark Kotter discusses the influence synthetic biology is having on the futu...

bit.bio secures foundational United States patent for opti-ox, its cell programming technology that uses genomic safe harbour site...

bit.bio's President and COO named as one of the 20 women reshaping biopharma R&D in 2023 report.

An article on synbio in the Summer 2023 issue of Science in Parliament magazine. Authored by our founder and CEO Mark Kotter.